CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aviceda Therapeutics (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators with a proprietary High Affinity ...
– Financing led by RA Capital Management with participation from existing investors and additional new investors, including AstraZeneca and Bristol Myers Squibb – SOUTH SAN FRANCISCO, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback